Discontinued — last reported Q3 '22
Pfizer Total Debt, Gross increased by 23.3% to $3.89B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.9%, from $4.47B to $3.89B. Over 5 years (FY 2020 to FY 2025), Total Debt, Gross shows an upward trend with a 3.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests higher leverage and potential financial risk, while a decrease indicates deleveraging and improved balance sheet strength.
This represents the aggregate principal amount of all short-term and long-term debt obligations owed by the company to e...
Standard across all capital-intensive industries; peers typically manage this relative to EBITDA.
total_debt_gross| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.89B | $3.63B | $2.24B | $636.00M | $5.97B | $4.02B | $2.94B | $4.17B | $3.97B | $2.54B | $10.47B | $8.29B | $12.03B | $9.75B | $6.96B | $4.47B | $4.30B | $4.31B | $3.16B | $3.89B |
| QoQ Change | — | -6.7% | -38.3% | -71.6% | +837.9% | -32.5% | -27.1% | +42.1% | -4.8% | -36.1% | +312.4% | -20.8% | +45.1% | -19.0% | -28.7% | -35.7% | -3.8% | +0.1% | -26.7% | +23.3% |
| YoY Change | — | — | — | — | +53.3% | +10.9% | +31.0% | +556.0% | -33.4% | -36.9% | +256.6% | +98.8% | +203.1% | +284.2% | -33.5% | -46.1% | -64.3% | -55.8% | -54.6% | -12.9% |